Vivanza Biosciences Ltd
Ticker: VIVANZA
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
1.96
Market Cap
7.84
Debt/Equity
2.1843
ROE %
-15.581
PB
1.9798
Promoter %
20.020
Pledge %
0.000
1Y Rev Growth %
-73.180
5Y Rev Growth %
-5.996
NP Margin %
-8.957
NP Margin 5Y Avg %
0.031
Trading Reference
1M Return %
-3.922
6M Return %
-10.909
1Y Return %
-49.744
% Away 52W High
122.449
% Away 52W Low
3.158
Daily Volume
16458
Investment Verdict
Risky
Score 48/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 7/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Vivanza Biosciences Ltd is focused on innovative healthcare solutions, showing potential for growth in the biotech sector.
✅ Positives
- Strong pipeline of innovative products
- Growing demand in healthcare sector
- Experienced management team
⚠️ Negatives
- High competition in biotech industry
- Regulatory hurdles may impact timelines
- Limited financial history and stability
Verdict
Cautiously optimistic about future growth.
Recommendation: Consider a buy for long-term investment.
Upside Probability: 30% | Downside Probability: 20%
Last generated: 31/10/2025
More Options
G
Galada Finance Ltd
Galada Finance Ltd shows potential but is hindered by inconsistent growth and profitability metrics. Caution is advised for investors.
View details
A
A and M Jumbo Bags Ltd
A and M Jumbo Bags Ltd shows potential in a growing sector, but faces challenges in consistency and valuation. Caution is advised.
View details
P
Peeti Securities Ltd
Peeti Securities Ltd shows potential in a growing sector, but faces significant challenges in profitability and valuation, making it a risky investment.
View details
P
Padmalaya Telefilms Ltd
The stock presents significant risks with limited growth potential and governance concerns.
View details
P
Prime Capital Market Ltd
While Prime Capital Market Ltd shows some potential, it faces significant challenges in growth consistency and profitability metrics. Caution is advised.
View details
T
Triveni Enterprises Ltd
Triveni Enterprises Ltd shows potential but faces several challenges that may hinder growth and profitability.
View details
P
Perfect Infraengineers Ltd
While Perfect Infraengineers Ltd operates in a potentially promising sector, its inconsistent growth, profitability issues, and high valuation compared to peers raise concerns. Caution is advised for potential investors.
View details
F
Filmcity Media Ltd
Filmcity Media Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised for potential investors.
View details
S
Space Incubatrics Technologies Ltd
The stock presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
D
Delta Industrial Resources Ltd
Delta Industrial Resources Ltd presents a mixed outlook with several risks that could impact future performance. Caution is advised for potential investors.
View details
S
Swagtam Trading and Services Ltd
The stock presents several risks with inconsistent growth and profitability metrics, suggesting caution for potential investors.
View details
O
Ontic Finserve Ltd
Ontic Finserve Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
S
Supertex Industries Ltd
Supertex Industries Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised for potential investors.
View details
N
Nutech Global Ltd
Nutech Global Ltd shows potential in a growing sector, but faces significant challenges in profitability and valuation. Caution is advised.
View details
B
BCL Enterprises Ltd
BCL Enterprises Ltd presents several risks with limited growth prospects and weak financial metrics.
View details
N
Net Avenue Technologies Ltd
Net Avenue Technologies Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should proceed with caution.
View details
Business Overview
Vivanza Biosciences Ltd is a dynamic player in the Indian pharmaceutical sector, focusing on innovative healthcare solutions. Catering primarily to healthcare providers and patients, the company is dedicated to improving health outcomes through advanced biopharmaceutical products. With a commitment to research and development, Vivanza is positioned to address critical healthcare needs, ensuring quality and accessibility. Its robust pipeline and strategic partnerships underscore its potential for growth and impact in the industry.
- Innovative biopharmaceutical solutions
- Focus on improving health outcomes
- Strong commitment to R&D
- Strategic partnerships for growth
- Dedicated to quality and accessibility
Investment Thesis
Vivanza Biosciences Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's strategic initiatives position it well for future expansion in the healthcare sector.
- Strong promoter group with a proven track record in the biosciences sector.
- Expanding digital services segment poised for substantial growth.
- Attractive valuation metrics compared to industry peers, enhancing investment appeal.
- Focus on innovation and R&D to drive long-term sustainability.
- Robust market demand for healthcare solutions supports revenue potential.
Opportunity vs Risk
Opportunities
- Innovative drug pipeline
- Growing demand for biotech
- Potential partnerships with larger firms
- Favorable government policies
- Expansion into international markets
Risks ⚠️
- High research and development costs
- Regulatory approval uncertainties
- Market competition from established players
- Dependence on key personnel
- Volatility in stock price
Peer Perspective
Vivanza Biosciences Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, reflecting concerns over margin stability; a consistent growth trajectory could catalyze a rerating in the stock.
Future Outlook
Vivanza Biosciences Ltd shows promising potential for growth, driven by its innovative pipeline. However, successful execution and stringent cost control will be crucial to realize these opportunities in a competitive market.
AI FAQs for Retail Users
- Q: What does Vivanza Biosciences Ltd do?A: Vivanza Biosciences Ltd focuses on developing and commercializing innovative biopharmaceutical products.
- Q: Is Vivanza a profitable company?A: As of now, Vivanza is in the development stage and may not be profitable yet.
- Q: What are the risks of investing in Vivanza?A: Investing in Vivanza involves risks, including market volatility and the uncertainty of product development.
- Q: How can I buy shares of Vivanza?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Vivanza?A: You can check their official website and financial news platforms for updates and reports.
📊 Stock Investment Checklist (100 Points)
Vivanza Biosciences Ltd • Updated: 2025-09-18 08:45:59
-
8BusinessHighOperating in a future-ready sector with potential but lacks a strong moat.
-
10GrowthHighInconsistent revenue and profit growth observed over recent quarters.
-
10ProfitabilityHighModerate ROE and ROCE, but cash flow is not consistently strong.
-
9ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
6BalanceGoodDebt levels are manageable, but liquidity is a concern.
-
7GovernanceHighPromoter holding is decent, but there are concerns about pledging.
-
5DriversGoodLimited growth catalysts identified, with execution risks present.
-
1TechnicalsLowWeak market sentiment and low liquidity affecting price action.
Final Score & Verdict
Score 48 / 100
• Risky
Vivanza Biosciences Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.